CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 2, March/April 2011
AFRICA
69
1984;
53
: 77C-81C.
5. Guiteras-Val P, Varas-Lorenzo C, Garcia-Picart J,
et al
. Clinical and
sequential angiographic follow-up six months and 10 years after success-
ful percutaneous transluminal coronary angioplasty.
Am J Cardiol
1999;
83
: 868.
6. Faxon DP. Systemic drug therapy for restenosis. ‘Deja vu’ all over again.
Circulation
2002;
106
: 2296–2298.
7. Harding SA, Walters DL, Palacios IF,
et al
. Adjunctive pharmacotherapy
for coronary stenting.
Curr Opin Cardiol
2001;
16
: 293–299.
8. Farb A, Sangiorgi G, Carter A,
et al
. Pathology of acute and chronic
coronary stenting in humans.
Circulation
1999;
99
: 44–52.
9. Libby P. Inflammation in atherosclerosis.
Nature
2002;
420
: 868–874.
10. Kornowski R, Hong MK, Tio FO,
et al
. In-stent restenosis: contributions
of inflammatory responses and arterial injury to neointimal hyperplasia.
J Am Coll Cardiol 1
998;
31
: 224–230.
11. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights
from experimental models
. Int J Exp Pathol
2000;
81
: 63–88.
12. Ross R. Atherosclerosis: an inflammatory disease.
N Engl J Med
1999;
340
: 115–126.
13. MacDonald RG, Panush RS, Pepine CJ. Rationale for use of glucocor-
ticoids in modification of restenosis after percutaneous transluminal
coronary angioplasty.
Am J Cardiol
1987;
60
: 56–60B.
14. Oppenheim E, Bruger M. The effect of cortisone and ACTH on
experimental cholesterol atherosclerosis in rabbits.
Circulation
1952;
6
: 470–471.
15. Ribichini F, Joner M, Ferrero V,
et al
. Effects of oral prednisone after
stenting in a rabbit model of established atherosclerosis.
J Am Coll
Cardiol
2007;
50
: 176–185.
16. Ferrero V, Ribichini F, Pesarini G,
et al
. Therapeutic potential of gluco-
corticoids in the prevention of restenosis after coronary angioplasty.
Drugs
2007;
67
: 1243–1255.
17. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids. New
mechanisms for old drugs.
N Engl J Med
2005;
353
: 1711–1723.
18. Stone GW, Rutherford BD, McConahay DR,
et al
. A randomized trial of
corticosteroids for the prevention of restenosis in 102 patients undergo-
ing repeat coronary angioplasty.
Cathet Cardiovasc Diagn
1989;
18
:
227–231.
19. Pepine CJ, Hirshfeld JW, Macdonald RG,
et al
. A controlled trial
of corticosteroids to prevent restenosis after coronary angioplasty.
Circulation
1990;
81
: 1753–1761.
20. Lee CW, Chae J, Lim H,
et al
. Prospective randomized trial of cortico-
steroids for the prevention of restenosis after intracoronary stent implan-
tation.
Am Heart J
1999;
138
: 60–63.
21. Versaci F, Gaspardone A, Tomai F,
et al
. Immunosuppressive therapy
for the prevention of restenosis after coronary artery stent implantation
(IMPRESS Study).
J Am Coll Cardiol
2002;
40
:1935–1942.
22. Ribichini F, Tomai F, Ferrero V,
et al
. Immunosuppressive oral pred-
nisone after percutaneous interventions in patients with multi-vessel
coronary artery disease. The IMPRESS-2/MVD Study.
Eurointervention
2005;
2
: 173–180.
23. Kakio T, Matsumori A, Ohashi N,
et al
. Hydrocortisone reduces resten-
osis after stenting of small coronary arteries.
J Interven Cardiol
2004;
17
: 295–300.
24. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid
therapy: the sharpening of an old spear.
Lancet
2005;
365
: 801–803.
25. Ferrero V, Ribichini F, Rognoni A,
et al
. Comparison of efficacy and
safety of lowered-dose to higher-dose oral prednisone after percutaneous
coronary intervention. The IMPRESS-LD Study.
Am J Cardiol
2007;
99
: 1082–1086.
26. Szefler SJ, Ebling WF, Georgitis JW,
et al
. Methyl prednisolone versus
prednisolone pharmacokinetics in relation to dose in adults.
Eur J Clin
Pharmacol
1986;
30
: 323–329.
It's the
shell that
makes
safer.
R
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
